TargetMol

Hydralazine hydrochloride

Product Code:
 
TAR-T1613
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T1613-100mg100mg£111.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T1613-200mg200mg£117.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Hydralazine Hydrochloride is the hydrochloride salt of hydralazine, a phthalazine derivative with antihypertensive and potential antineoplastic activities. Hydralazine alters intracellular calcium release and interferes with smooth muscle cell calcium influx, resulting in arterial vasodilatation. This agent also inhibits the phosphorylation of myosin protein and chelation of trace metals required for smooth muscle contraction, resulting in an increase in heart rate, stroke volume, and cardiac output. In addition to its cardiovascular effects, hydralazine inhibits DNA methyltransferase, which may result in inhibition of DNA methylation in tumor cells.
CAS:
304-20-1
Formula:
C8H9ClN4
Molecular Weight:
196.64
Pathway:
Metabolism; Neuroscience; Chromatin/Epigenetic
Purity:
0.9986
SMILES:
Cl.NNc1nncc2ccccc12
Target:
MAO; HIF/HIF Prolyl-Hydroxylase

References

1. Mazari L, et al. Proc Natl Acad Sci U S A,2007, 104(15), 6317-6322. 2. Burcham PC, et al. Mol Pharmacol,2006, 69(3), 1056-1065. 3. Leiro JM, et al. Int Immunopharmacol,2004, 4(2), 163-177. 4. Hamann K, et al. J Neurochem,2008, 104(3), 708-718. 5. Kaminskas LM, et al. J Pharmacol Exp Ther,2004, 310(3), 12003-12010.